<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576859</url>
  </required_header>
  <id_info>
    <org_study_id>18-AOI-11</org_study_id>
    <nct_id>NCT03576859</nct_id>
  </id_info>
  <brief_title>Pyrophosphate Homeostasis and Hepatic Expression of ABCC6.Pyro-TH</brief_title>
  <acronym>Pyro-TH</acronym>
  <official_title>Pyrophosphate Homeostasis and Hepatic Expression of ABCC6. Pilot Study in Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In animals, normal hepatic expression of ABCC6 (ATP-binding transporter cassette, subfamily
      C, member 6) determines plasma pyrophosphate (PPi) concentration. PPi prevents the formation
      of hydroxyapatite crystals on tissues by precipitation of calcium and inorganic phosphate
      (Pi). It is an endogenous compound whose deficiency causes diffuse vascular calcifications in
      certain rare monogenic diseases, including the elastic pseudoxanthoma caused by the mutation
      of ABCC6. PPi is produced by enzymatic transformation of extracellular ATP and, in animals,
      the liver is the main supplier of ATP and PPi (more than 90%). In humans, liver
      transplantation offers the possibility of correlating the plasma concentration of PPi
      ([PPi]pl) with hepatic expression of ABCC6. Liver transplantation is performed in the
      treatment of chronic liver failure (Child B or C) or, in the absence of liver failure, in the
      treatment of hepatocellular carcinoma. By measuring[PPi]pl before transplantation and after
      liver function restoration and by measuring ABCC6 in the diseased liver and healthy liver, it
      is possible to determine whether liver failure is associated with decreased[PPi]pl and
      decreased liver expression of ABCC6, which is the objective of our pilot study. Its interest
      is to establish a physiopathological link between the frequent vascular calcifications in
      obese patients with hepatic steatosis and the production of PPi.

      prupose: Look for a deficit in[PPi]pl in patients before the transplant compared to the phase
      of restoration of liver function
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">November 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma PPi concentration between before transplantation and liver function restoration in the both arms</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>cirrhotic patients with chronic liver failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhotic patients without chronic liver failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Peripheral venous blood is collected before liver transplantation and after restoration of liver function</description>
    <arm_group_label>cirrhotic patients with chronic liver failure</arm_group_label>
    <arm_group_label>cirrhotic patients without chronic liver failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Indication for liver transplantation Age greater than or equal to 18 years Patients
        affiliated to social security

        Exclusion Criteria:

        Patient not affiliated to social security Non-consenting patient or unable to understand
        the protocol and how it works Fulminant Hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio IANNELLI, PHD</last_name>
    <phone>33 492 03 60 44</phone>
    <email>iannelli.a@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Untiversity Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio IANNELLI, PHD</last_name>
      <phone>33 4 92 03 40 66</phone>
      <email>iannelli.a@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Guillaume FAVRE, MCUPH</last_name>
      <phone>33 4 92 03 84 28</phone>
      <email>favre.g@chu-nice.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

